{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.8","value":"237"},{"groupId":"OG001","spread":"21","value":"525"},{"groupId":"OG002","spread":"32.5","value":"1020"},{"groupId":"OG003","spread":"24.1","value":"1900"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"48"},{"groupId":"OG003","value":"47"}],"units":"Participants"}],"description":"Steady state is achieved when the rate of drug input is equal to the rate of drug elimination. The AUC(tau,ss) at 1 dosing interval is the average concentration of the drug at steady state multiplied by the time of the dosing interval.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG000","title":"1 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"OG001","title":"2 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG002","title":"4 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"OG003","title":"8 mg Baricitinib (LY3009104)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who received any study drug and had evaluable data for AUC(tau,ss).","reportingStatus":"POSTED","timeFrame":"Weeks (Wks) 0, 8, 12, or 20: Predose, 15 to 30 minutes and 1 to 3 hours postdose; Wks 2 or 4 and 15 or 16: Predose; Wks 28, 40, 52, or 64: random single sample.","title":"Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104","type":"SECONDARY","unitOfMeasure":"nanomoles*hour (nM*h)"}